Venture capital fund · 4 deals
Every published round Canaan Partners took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Sumble | Series A | 24 Oct 2025 | $46m | Lead | Startup Daily, SmartCompany, Square Peg Capital portfolio | |
| World View | Series D+ | 15 May 2024 | $37m | Participant | SmartCompany, Startup Daily (Tue 15 Sep 2026), Startup Daily (Mon 4 Nov 2024), Startup Daily (Wed 19 Jun 2024), Startup Daily (Thu 16 May 2024), Breakthrough Victoria (Thu 16 May 2024), Breakthrough Victoria (Fri 3 May 2024), Breakthrough Victoria (Fri 3 May 2024) | |
| Pathios Therapeutics | Series B | 1 May 2024 | $25m | Participant | biomelbourne.org, Brandon Capital portfolio | |
| Spinifex Pharmaceuticals | Series C | 13 May 2014 | $45m | Participant | bionity.com, GBS Ventures (Tue 30 Jun 2015), clinicalleader.com, GBS Ventures (Tue 13 May 2014) |
Companies Canaan Partners has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Pathios Therapeutics | 1 May 2024, Series B | 1 | 0 | |
| Spinifex Pharmaceuticals | 13 May 2014, Series C | 1 | 0 | |
| Sumble | 24 Oct 2025, Series A | 1 | 1 | |
| World View | 15 May 2024, Series D+ | 1 | 0 |
Fund closes reported for Canaan Partners, as distinct from the investments it has made.
Companies Canaan Partners has backed that another company then bought. An exit for the holding, not a deal Canaan Partners did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| Spinifex Pharmaceuticals | Novartis International | Acquisition | 29 Jun 2015 | $200m+ |
| Spinifex Pharmaceuticals | Novartis | Acquisition | 29 Jun 2015 | $700m |
Stories naming Canaan Partners. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Roundup of a quiet funding week: Melbourne workforce-platform maker 2cloudnine banked over $7.5m, algae-ingredient maker SeaStock $740,000 from government accelerator FaBA, while San Francisco's Sumble emerged with $59m.
Also Startup Daily
Pathios Therapeutics has begun treating patients in an Australian Phase 1/2 trial of its GPR65 inhibitor PTT-4256 for advanced solid tumours. Backers to date include Canaan, Brandon Capital and Bristol Myers Squibb.
Pathios Therapeutics has dosed the first patient in a Phase 1/2 trial of its GPR65 inhibitor PTT-4256, run by its Australian team; the company also cites US$58M raised to date.
Cancer immunotherapy biotech Pathios Therapeutics has completed the initial tranche of a Series B round, bringing in Bristol Myers Squibb as a new strategic backer alongside prior backers Canaan and Brandon Capital.
UK cancer biotech Pathios Therapeutics, backed by Canaan Partners and Brandon Capital, presented preclinical data at a US conference showing its GPR65 inhibitor PTT-3213 shrank tumors in mouse models.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·novartis.com·clinicalleader.com·Brandon Capital portfolio·Startup Daily·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia
Pain-drug developer Spinifex Pharmaceuticals hires Dr Ronald Marcus as chief medical officer; CEO Tom McCarthy cites a recent $45 million raise backing further phase 2 trials of EMA401.